2026-09-26 03:34:55 UTC#371726newconfirmednews
Merck (MRK) stock news
Merck (MRK) stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-09-25 21:45:42 UTC#371245duplicateconfirmednews
Merck and Daiichi Sankyo voluntarily withdraw US BLA for ifinatamab deruxtecan in ES-SCLC
reutersimportance 0.40trust 0.90Merck & Co., Inc. -0.40Daiichi Sankyo Company, Limited -0.40Ifinatamab deruxtecan -0.50+2 entities
2026-09-25 21:18:00 UTC#371152duplicateconfirmednews
Merck and Daiichi Sankyo Withdraw FDA Application for Lung Cancer Drug Ifinatamab Deruxtecan
dow_jonesimportance 0.40trust 0.90Merck & Co., Inc. -0.40Daiichi Sankyo Company, Limited -0.40Food and Drug Administration -0.20+1 entities
2026-09-25 21:07:42 UTC#371141duplicateconfirmednews
Merck and Daiichi Sankyo withdraw US BLA for lung cancer drug ifinatamab deruxtecan
seekingalpha.comimportance 0.30trust 0.80Merck & Co., Inc. -0.40Daiichi Sankyo Company, Limited -0.40ifinatamab deruxtecan -0.50
2026-09-25 21:07:42 UTC#371112duplicateconfirmednews
Merck and Daiichi Sankyo withdraw US BLA for lung cancer drug ifinatamab deruxtecan
2026-09-25 20:43:02 UTC#371005duplicateconfirmednews
Merck and Daiichi Sankyo withdraw US application for lung cancer therapy ifinatamab deruxtecan
reutersimportance 0.40trust 0.90Merck & Co., Inc. -0.40Daiichi Sankyo Company, Limited -0.40U.S. Food and Drug Administration -0.20+1 entities
2026-09-25 20:41:51 UTC#371031duplicateconfirmednews
Merck and Daiichi Sankyo withdraw US application for lung cancer drug ifinatamab deruxtecan
2026-09-25 20:37:26 UTC#370974duplicateconfirmednews
Merck and Daiichi Sankyo withdraw US application for lung cancer drug ifinatamab deruxtecan
2026-09-25 20:30:00 UTC#370957duplicateconfirmednews
Merck & Co. withdraws US BLA for ifinatamab deruxtecan in ES-SCLC after FDA feedback
tradingviewimportance 0.40trust 0.80Merck & Co., Inc. -0.50ifinatamab deruxtecan -0.60Food and Drug Administration 0+1 entities
2026-09-25 20:30:00 UTC#370956newconfirmednews
Daiichi Sankyo withdraws US BLA for ifinatamab deruxtecan in ES-SCLC after FDA feedback
tradingviewimportance 0.60trust 0.80Daiichi Sankyo Company, Limited -0.50Merck & Co., Inc. -0.30ifinatamab deruxtecan -0.50+2 entities
2026-09-25 11:04:00 UTC#368134duplicateconfirmednews
Merck and Eisai receive FDA approval for Welireg and Lenvima combination in advanced kidney cancer
dow_jonesimportance 0.30trust 0.90Merck & Co., Inc. +0.50Eisai Co., Ltd. +0.50U.S. Food and Drug Administration 0+2 entities
2026-09-25 10:47:18 UTC#368067duplicateconfirmednews
FDA approves Merck's Welireg and Eisai's Lenvima combination for advanced renal cell carcinoma
reutersimportance 0.40trust 0.90Merck & Co., Inc. +0.50U.S. Food and Drug Administration 0Welireg +0.50+1 entities
2026-09-25 10:45:00 UTC#368050duplicateconfirmednews
Merck and Eisai receive FDA approval for WELIREG and LENVIMA combination in advanced ccRCC
tradingviewimportance 0.30trust 0.70Merck & Co., Inc. +0.60Eisai Co., Ltd. +0.50Food and Drug Administration +0.40+1 entities
2026-09-24 20:32:12 UTC#365399duplicateconfirmednews
FDA approves Merck's Welireg and Eisai's Lenvima combination for advanced renal cell carcinoma
seeking alphaimportance 0.30trust 0.80Merck & Co., Inc. +0.50Eisai Co., Ltd. +0.50Welireg +0.50+1 entities
2026-09-24 19:17:47 UTC#364982newconfirmednews
FDA approves Merck's Welireg (belzutifan) and Eisai's Lenvima (lenvatinib) for advanced renal cell carcinoma
fast_stock_market_newsimportance 0.70trust 0.80Merck & Co., Inc. +0.60Eisai Co., Ltd. +0.60Belzutifan +0.60+2 entities
2026-09-24 11:27:00 UTC#361899duplicateconfirmednews
Merck reports positive Phase 2b/3 trial results for remigromig in diabetic macular edema patients
dow_jonesimportance 0.30trust 0.80Merck & Co., Inc. +0.50remigromig +0.50diabetic macular edema +0.50
2026-09-24 11:12:00 UTC#361789duplicateconfirmednews
Merck reports positive Phase 2b/3 trial results for remigromig in diabetic macular edema patients
2026-09-24 11:05:08 UTC#361760duplicateconfirmednews
Merck eye disease drug meets primary endpoint in clinical trial
2026-09-24 11:04:39 UTC#361738duplicateconfirmednews
Merck's remigromig meets primary endpoint in diabetic macular edema trial
2026-09-24 10:52:30 UTC#361685duplicateconfirmednews